Enumera Molecular provides the EnumeraPlex™ platform to simplify complex, high-analyte molecular testing for clinical use. This technology enables simplified, cost-effective workflows for liquid biopsy and broad clinical genomic applications in any laboratory. The platform delivers high-performance pan-omic detection without PCR bias and eliminates the need for complex bioinformatics analysis.
Funding
$18.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current high-dimensionality platforms for clinical omics, such as whole genome sequencing, require massive input, complex workflows, and high operational costs, limiting the accessibility of precision medicine. These complexities restrict the democratization of liquid biopsy and other advanced clinical genomic applications.
Solution
Enumera Molecular's EnumeraPlex™ platform simplifies complex lab workflows to enable rapid and cost-effective liquid biopsy tests for clinical diagnostics. The platform reduces operational costs and input requirements, making precision medicine more accessible to laboratories. EnumeraPlex™ empowers any lab with simplified testing across broad clinical genomic applications, redefining complex testing through its unique technology and workflow.
Target Audience
The primary target audience includes clinical diagnostic laboratories seeking to implement cost-effective and rapid liquid biopsy tests.
Features
- Scalable molecular counting technology for rapid and cost-effective liquid biopsy tests.
- Simplified workflows in clinical omics, reducing operational costs and input requirements.
- Enables high-dimensional assays for broad clinical genomic applications.